Mydriasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Mydriasis Market Outlook
Thelansis’s “Mydriasis Market Outlook,
Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034"
covers disease overview, epidemiology, drug utilization, prescription share
analysis, competitive landscape, clinical practice, regulatory landscape,
patient share, market uptake, market forecast, and key market insights under
the potential Mydriasis treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
Mydriasis Overview
Mydriasis
and pupil dilation can result from various causes, including non-physiological
factors like disease, trauma, drug use, or as part of the normal pupillary
response. An agent called a mydriatic is commonly used to induce pupil
dilation, primarily for facilitating retina examinations and other deep eye
structures. In general medical practice, the most common reason for pupil
dilation is screening for diabetic retinopathy, followed by macular
degeneration. This condition can also occur as a symptom of brain injury
resulting from physical trauma or stroke, affecting one pupil individually or
both simultaneously. The process of pupillary dilation is governed by the iris
dilator muscle, composed of radially oriented fibers that connect the iris’s
exterior to its interior. When the dilator muscle contracts, it pulls the
iris’s interior outward, enlarging the pupil’s size. Additionally, the iris
dilator muscle is under the control of the sympathetic nervous system, which is
a part of the autonomic nervous system responsible for arousal, wakefulness,
and the fight or flight response.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment